8-K: FOXO Technologies Faces Delisting Threat After Failing to File Annual Report

FOXO Technologies has received a notice from the NYSE American for failing to file its annual report, placing its listing status at risk.

Summary

• FOXO Technologies received a notice of noncompliance from the NYSE American because it did not file its annual report for the year ended December 31, 2023, by the deadline of April 16, 2024.
• The company is now subject to the procedures outlined in Section 1007 of the NYSE American Company Guide.
• FOXO has an initial six-month period to rectify the filing delinquency.
• If the company fails to cure the delinquency within the initial period, the NYSE may grant an additional six-month period, or may commence delisting procedures.
• The NYSE has the discretion to shorten or eliminate the cure periods and immediately begin delisting procedures if it deems continued listing is unwarranted.
• The company states it intends to regain compliance with the NYSE American continued listing standards, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting threat and the company's failure to meet filing deadlines. While the company expresses commitment to regaining compliance, the situation introduces significant uncertainty and risk.

Positives

• FOXO is committed to regaining compliance with NYSE American listing standards.
• The company has implemented measures to improve financial systems and corporate governance.
• FOXO is actively pursuing a potentially transformative transaction to benefit shareholders.
• The company has made considerable operational and financial progress despite the challenges.

Negatives

• FOXO failed to file its annual report by the required deadline, resulting in a non-compliance notice.
• The company faces the risk of suspension and delisting from the NYSE American if it does not regain compliance.
• There is no assurance that FOXO will ultimately regain compliance with all applicable listing standards.
• The delay in filing is attributed to significant changes and restructuring, indicating potential internal challenges.

Risks

• There is a risk that the company will not be able to regain compliance with NYSE American listing standards.
• The NYSE may decide not to grant an additional cure period, or may shorten the cure period, leading to immediate delisting procedures.
• The company's ongoing restructuring and changes may continue to cause delays in financial reporting.
• The company's ability to execute its business plans and achieve profitability is subject to various risks and uncertainties.
• The company operates in a highly competitive and regulated industry, which presents additional challenges.

Future Outlook

The company intends to regain compliance with NYSE American listing standards and is working to improve its financial systems and corporate governance. They are also advancing a potentially transformative transaction. However, there is no guarantee of success.

Management Comments

• Mark White, Interim CEO of Foxo Technologies, explained that the delay in filing the Form 10-K was due to significant changes and essential restructuring undertaken in 2023, which has continued in 2024.
• The company is fully dedicated to meeting the NYSE Americans continued listing requirements and has implemented measures to greatly improve our financial systems and ensure the highest levels of corporate governance.
• The company continues to advance a potentially transformative transaction that it believes would drive significant value for its shareholders.

Industry Context

This announcement highlights the importance of timely financial reporting for publicly listed companies. Failure to meet deadlines can lead to significant consequences, including potential delisting. This situation is not unique to FOXO, as other companies have faced similar challenges, underscoring the need for robust internal controls and financial management.

Comparison to Industry Standards

• The failure to file an annual report on time is a significant breach of listing requirements, which are designed to ensure transparency and accountability for investors.
• Companies like BioTime (now AgeX Therapeutics) and others have faced similar delisting threats due to non-compliance with filing deadlines, highlighting the importance of maintaining timely financial reporting.
• The standard cure period of six months, with a possible extension, is typical for companies facing such issues, but the NYSE's discretion to shorten or eliminate this period adds uncertainty.
• Compared to companies with strong internal controls and financial reporting processes, FOXO's situation indicates potential weaknesses in its systems.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in share value.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and suppliers may be concerned about the company's long-term viability.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• FOXO must contact the NYSE to discuss the status of the delinquent report.
• The company must file its annual report to cure the filing delinquency.
• FOXO will be monitored by the NYSE during the cure period.
• The company will provide further updates on its progress.

Key Dates

Keywords

Delisting, NYSE American, Non-compliance, Annual Report, Financial Reporting, Listing Standards, FOXO Technologies, Restructuring, Corporate Governance